Marshall Wace LLP acquired a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 76,254 shares of the company's stock, valued at approximately $1,010,000.
Other hedge funds have also modified their holdings of the company. Versant Capital Management Inc acquired a new position in Takeda Pharmaceutical in the 4th quarter worth about $26,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in Takeda Pharmaceutical in the 4th quarter valued at $52,000. Finally, Cromwell Holdings LLC purchased a new stake in Takeda Pharmaceutical in the 4th quarter worth $61,000. 9.17% of the stock is owned by hedge funds and other institutional investors.
Takeda Pharmaceutical Price Performance
TAK stock traded down $0.18 during trading on Tuesday, hitting $15.20. The stock had a trading volume of 2,297,882 shares, compared to its average volume of 1,875,061. The company's 50-day moving average price is $14.88 and its two-hundred day moving average price is $13.98. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.43. The stock has a market capitalization of $48.36 billion, a P/E ratio of 38.00, a PEG ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.
View Our Latest Stock Report on Takeda Pharmaceutical
Takeda Pharmaceutical Company Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
